Xing Li

机构：Shaoyang University · ORCID：0000-0003-1935-7766

发表论文 116 篇 · 总被引 1496 次 · h-index 23

代表论文

• Clinical approaches to overcome PARP inhibitor resistance (2025 · Molecular Cancer · 被引 82)
• Vitamin D inhibits ferroptosis and mitigates the kidney injury of prediabetic mice by activating the Klotho/p53 signaling pathway (2024 · APOPTOSIS · 被引 29)
• The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study (2024 · Journal of Gastroenterology and Hepatology · 被引 25)
• Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial (2025 · Nature Medicine · 被引 20)
• Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus (2023 · Biomedicine & Pharmacotherapy · 被引 19)
• Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial (2025 · The Lancet Infectious Diseases · 被引 10)